this post was submitted on 18 Jan 2024
99 points (98.1% liked)

science

14767 readers
82 users here now

A community to post scientific articles, news, and civil discussion.

rule #1: be kind

<--- rules currently under construction, see current pinned post.

2024-11-11

founded 1 year ago
MODERATORS
you are viewing a single comment's thread
view the rest of the comments
[–] solrize@lemmy.world 18 points 10 months ago

Exa-cel, also known by its brand name Casgevy, received its first regulatory approval on Nov. 16, 2023 from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to treat two debilitating blood disorders: sickle-cell disease and transfusion-dependent beta-thalassemia. The U.S. Food and Drug Administration (FDA) later approved the therapy as a treatment for both disorders.